Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Search Results for: clinical trials – Page 38

ASH 2020 Satellite Symposia Update

This year is unusual in so many ways, with all of the meetings being virtually, yet much of the content being broadcast live. Here are my quick notes from what is really day -1 of ASH.

ASH 2019: Dr. Krish Patel on Harnessing the Immune System in Chronic Lymphocytic Leukemia (CLL) and Other Lymphomas Using Bispecific Antibodies

Dr. Brian Koffman interviewed Dr. Krish Patel at ASH 2019, about how our native immune system is excellent at controlling cancer when it is working normally. In CLL, the immune system has become dysregulated and does a poor job controlling cancer. Could modifying the immune system with off-the-shelf bi-specific antibodies repair this problem?

ASCO 2020 Top 12” #8: Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study

At ASCO 2020 the final results of the GENUINE trial were reported 3 ½ years out after adding to ibrutinib, the monoclonal antibody (MAB), ublituximab. Ublituximab is directed against CD20, a surface marker found on B-lymphocytes, both normal and cancerous, including CLL cells. UTX was specifically engineered to increase its ability to kill its target cells.Dr. Brian Koffman explains.

Didn't find what you where looking for?

Try our advanced search page!